Shandong Sito Bio-technology Co

Shandong Sito Bio-technology Co OCF Margin

The Operating Cash Flow Margin of Shandong Sito Bio-technology Co (300583.SZ) as of Nov 3, 2026 is 15.59 %. In the previous year, Operating Cash Flow Margin was 20.03 % — a change of -22.19% (lower).

OCF Margin

15.59 %

YoY

-22.19%

Last updated:

Operating Cash Flow Margin of Shandong Sito Bio-technology Co is 2025 15.59 % . Operating Cash Flow Margin of Shandong Sito Bio-technology Co was 2024 20.03 % . It decreases by -22.19% lower compared to the previous year.

The Shandong Sito Bio-technology Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-31.78 CNY
Jan 1, 2019
5.97 CNY
Jan 1, 2020
27.88 CNY
Jan 1, 2021
18.90 CNY
Jan 1, 2022
11.08 CNY
Jan 1, 2023
-7.25 CNY
Jan 1, 2024
20.03 CNY
Jan 1, 2025
15.59 CNY
The Shandong Sito Bio-technology Co OCF Margin history
YEAROCF MarginYoY
15.59 %-22.19%
20.03 %-376.16%
-7.25 %-165.50%
11.08 %-41.41%
18.90 %-32.19%
27.88 %+367.35%
5.97 %-118.77%
-31.78 %-2,391.18%
1.39 %-90.17%
14.10 %+8.19%
13.04 %-61.07%
33.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shandong Sito Bio-technology Co Stock analysis

What does Shandong Sito Bio-technology Co do? Shandong Sito Bio-technology Co., Ltd. generates revenue through three product segments. The Steroid Raw Materials segment produces steroid raw materials like androstenedione and 9-hydroxyandrostenedione using genetic engineering and microbial transformation technology. The Steroidal Finished Drug segment and Non-Steroidal Finished Drug segment are operated via its subsidiary, offering finished pharmaceutical products. The company's primary customers are pharmaceutical manufacturers requiring raw materials and finished drugs for further processing. The Steroid Raw Materials segment focuses on manufacturing key compounds such as androstenedione, hydroxyprogesterone, and 9-hydroxyandrostenedione. These materials are essential for the production of various steroid-based pharmaceuticals. The Steroidal Finished Drug segment provides ready-to-use pharmaceutical products, while the Non-Steroidal Finished Drug segment offers non-steroid alternatives, targeting different medical needs. Shandong Sito serves pharmaceutical companies that need raw materials for steroid-based drugs and finished drugs for distribution. The Steroid Raw Materials segment supplies critical inputs for steroid pharmaceutical production, while the Steroidal and Non-Steroidal Finished Drug segments cater to end-market demand for completed pharmaceutical products. The company's operations are centered around biotechnology-driven manufacturing of pharmaceutical ingredients and finished drugs. Shandong Sito Bio-technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shandong Sito Bio-technology Co stock

Operating Cash Flow Margin of Shandong Sito Bio-technology Co is 15.59 % in 2025.

Operating Cash Flow Margin of Shandong Sito Bio-technology Co changed from 20.03 % to 15.59 %, representing a -22.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Shandong Sito Bio-technology Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Shandong Sito Bio-technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Shandong Sito Bio-technology Co

All Key Metrics — Shandong Sito Bio-technology Co